Pfizer Acquire Global Blood Therapeutics for $5.4 Billion
9 August 2022
Collaborations, Mergers & Acquisitions
Finance & Investment
Pfizer has announced it is to acquire Global Blood Therapeutics (GBT), entering into a definitive agreement with the biopharmaceutical company to develop and deliver transformative therapies to patients of sickle cell disease (SCD).
Pfizer is to acquire GBT’s outstanding shares at $68.50 each, totaling an enterprise value of roughly $5.4 billion. The expected cash in hand transaction has unanimously been approved by the Board of Directors of both companies, subject to customary closing conditions.
GBT’s leading product portfolio and pipeline for SCD adds to Pfizer’s 30 years of experience serving the patient communities of rare hematological diseases.
“We are excited to welcome GBT colleagues into Pfizer and to work together to transform the lives of patients, as we have long sought to address the needs of this underserved community. The deep market knowledge and scientific and clinical capabilities we have built over three decades in rare hematology will enable us to accelerate innovation for the sickle cell disease community and bring these treatments to patients as quickly as possible,” said Albert Bourla, Chairman and CEO of Pfizer.
SCD is an inherited blood disorder causing hemolytic anemia, vaso-occlusive crisis (VOCs) and progressive organ failure, with a shortened life expectancy.
Early intervention and SCD treatments have been demonstrated to successfully reduce symptoms and extend life expectancy. However, there has been a historic unmet need for SCD-targeting therapies to help the 4.5 million people worldwide living with this disorder, predominantly in populations of African, Middle Eastern and South Asian descent.
In November 2019 GBT’s Oxbryta tablets were approved in the U.S. for SCD. This first-in-class medicine directly targets the root cause of SCD, and has since been approved in the EU, UAE, Oman and GB, with net sales from 2021 reaching approximately $195 million.
The acquisition will see Pfizer use its global platform to accelerate the distribution of Oxbryta, reaching the parts of the world with the largest populations of SCD.
“Pfizer will broaden and amplify our impact for patients and further propel much-needed innovation and resources for the care of people with sickle cell disease and other rare diseases, including populations in limited-resource countries,” commented Ted W. Love, President and CEO of GBT.
Pfizer will also be acquiring GBT’s promising pipeline including GBT021601, and inclacumab, both of which have received Orphan Drug and Rare Pediatric Disease designations from the FDA.
GBT021601 is a next-generation sickle hemoglobin (HbS) polymerizing inhibitor currently under Phase II clinical trial treating hemolysis and VOCs, and inclacumab is a human monoclonal antibody targeting P-selectin, currently under evaluation in 2 Phase III trials against VOCs.
Following the potential future approval of GBT021601 and inclacumab, total sales of Pfizer’s acquired SCD therapies, including Oxbryta, are expected to reach more than $3 billion worldwide.
GBT’s Ted Love concludes: “Today is an exciting milestone that accelerates GBT’s mission to discover, develop and deliver life-changing treatments that provide hope to underserved patient communities. We look forward to working together with Pfizer to serve our communities and advance our shared goal of improving health equity and expanding access to life-changing treatments to create a healthier future for all.”
The contract and research organization (CRO) AmplifyBio has announced the acquisition of select assets from privately held biopharmaceutical company PACT Pharma Inc to advance its cell and gene therapy service offerings.
For this Article, Phacilitate Editor, Georgi Makin, explores current challenges associated with CAR-T manufacturing workflows, considering how an integrated testing approach could reduce costs and accelerate speed to market.